Source: CureToday articles
A phase 1 trial evaluating SENTI-202 demonstrated positive preliminary results in treating relapsed/refractory acute myeloid leukemia.
Recent Content
- (no title)
- New center promotes advocacy for gynecological cancer patients
- FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
- TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
- (no title)
- (no title)
- New ‘powerful’ lab test will help researchers explore blood cancer
- Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters
- Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance